| 摘要 |
Novel compounds of the formula <FORM:1057290/C2/1> (wherein R is C1- 4 alkyl and Am is amino, hydrazino, guanidino, mono- or di-C1- 4 alkylamino, di-C1- 4 alkyl-alkyleneamino, arylamino-alkyleneamino - 1 - pyrrolidinyl, piperidino, morpholino, 1 - piperazinyl, 4 - C1- 4 alkyl-1 - piperazinyl, 4 - aryl - 1 - piperazinyl, 4 - aralkoxycarbonyl - 1 - piperazinyl, 4 - hydroxy-C1- 4 alkyl - 1 - piperazinyl, 4 - C1- 4 alkoxycarbonyl - 1 - piperazinyl or 4 - phenyl - 1,2,5,6-tetrahydropyridino) and acid - addition salts thereof, are prepared (1) from the corresponding acids or their alkyl esters, azides or anhydrides with alkanoic acids, by reaction with the appropriate AmH compounds; (2) by N-alkylation of the corresponding N-unsubstituted pyrrolidine compounds (prepared as in (3) following); (3) by reduction of the corresponding quaternary pyrrolinium compounds (prepared by N-alkylation). Compounds of the formula <FORM:1057290/C2/2> are prepared by reacting 3-dimethylamino-31,41-dimethoxy-propiophenone hydrochloride with dimethyl sulphate and then diethylacetamido-malonate to give diethyl acetamido-[3-(3,4-dimethoxyphenyl) - 3 - oxo - propyl]-malonate, cyclizing this with acid to 2-(3,4-dimethyloxyphenyl) - pyrroline - 5 - carboxylic acid hydro-chloride, converting this if desired to an ester, alkylating to give a 1-alkyl-2-(3,4-dimethoxyphenyl) -5-carboxy-pyrrolinium halide or ester thereof and reducing these. The esters may also subsequently be hydrolysed to the acids. These processes are all referred to in more general terms. The pyrrolidine derivatives of the invention, which are stated to exhibit spasmolytic, cardio-vascular, hypotensive and/or anti-secretory activities, may be made up into pharmaceutical compositions for peroral or parenteral administration with suitable carriers. |
